Journal article
The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial
L Zhang, J Coombes, EM Pascoe, SV Badve, K Dalziel, A Cass, P Clarke, P Ferrari, SP McDonald, AT Morrish, E Pedagogos, V Perkovic, D Reidlinger, A Scaria, R Walker, LA Vergara, CM Hawley, DW Johnson
Redox Report | Published : 2016
Abstract
Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients. Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities. Results: Pentoxifylline did not si..
View full abstractGrants
Funding Acknowledgements
The HERO trial was funded by research grants from Roche Foundation for Anaemia Research (RoFAR), Amgen, Janssen-Cilag and the National Health and Medical Research Council of Australia. The funders had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.